Key | % Net Assets |
---|---|
BG Group | 5.5% |
GlaxoSmithKline | 5.4% |
AstraZeneca | 4.8% |
Vodafone | 4.8% |
Other | 79.5% |
Name | % Net Assets |
---|---|
BG Group | 5.5% |
GlaxoSmithKline | 5.4% |
AstraZeneca | 4.8% |
Vodafone | 4.8% |
BP | 4.5% |
Royal Dutch Shell | 4.2% |
HSBC | 3.0% |
Barclays PLC | 2.6% |
BT Group | 2.6% |
Rio Tinto | 2.2% |
No asset data available.
Date | 02-Mar-2022 |
---|---|
NAV | 733.50p |
Currency | GBP |
Change | -13.90p |
% | -1.86% |
YTD change | 733.50p |
YTD % | n/a |
Fund Inception | 19/11/1969 |
---|---|
Fund Manager | Humphrey Van Der Klugt |
TER | 1.67 (20-Jun-2012) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | 5.25% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.10 |
You are here: research